BioPharmSignal logoBioPharmSignal

Biotech News

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

SeaStar Medical (ICU)SeaStar MedicalEarnings

SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its third quarter financial results after market close on Wednesday, November 11, 2026, and host a webcast and conference call to discuss its financial results and business progress.

Related news

IRIXIRIDEX2026-11-03 21:05 EST

Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026

TMCITreace Medical Concepts2026-10-23 11:05 EST

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

DNLIDenali Therapeutics2026-10-22 20:01 EST

Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026

SGHTSight Sciences2026-10-21 20:05 EST

Sight Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026

OMOutset Medical2026-10-21 20:05 EST

Outset Medical to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

RXSTRxSight2026-10-20 20:05 EST

RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3

STXSStereotaxis2026-10-20 11:40 EST

Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026

IRTCiRhythm2026-10-15 20:05 EST

iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026

ADPTAdaptive Biotechnologies2026-10-14 20:05 EST

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

View all latest news

SeaStar Medical

Organ-Failure Immunomodulation Company SeaStar Medical develops extracorporeal therapies for critically ill patients with organ failure and dysregulated inflammation. Selective Cytopheretic Device The Selective Cytopheretic Device is incorporated into continuous renal replacement therapy circuits and is designed to reduce the activity of...

Recent company news

ICUSeaStar Medical2026-11-04 13:41 EST

SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026

ICUSeaStar Medical2026-11-03 13:21 EST

FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients

ICUSeaStar Medical2026-10-07 12:16 EST

FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition

ICUSeaStar Medical2026-10-05 12:00 EST

SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds

ICUSeaStar Medical2026-10-02 13:43 EST

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

Stock data

Close
1.92 USD
Market cap
14.11M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States